Scientists reveal how cancer cells manipulate RNA splicing, increasing tumor growth. A new study introduces antisense ...

Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA ...

A University of Alberta research team has taken the first step toward proving its innovative gene therapy can successfully ...

A recent study by researchers from Nanyang Technological University identified Fanconi anemia complementation group M (FANCM) as a crucial regulator of alternative lengthening of telomere (ALT), ...

Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...